IDH inhibitors may be an effective and manageable treatment for rare tumors with usually poor prognosis (e.g., SNUCs [141]) but also an alternative treatment in diseases where standard treatments may have a heavy burden of morbidities (such as radiotherapy-related cognitive impairment for gliomas). This evidence concerns the gene IDH1 and glioma.